ASX-listed Mesoblast jumps as US FDA paves way for heart failure drug

ASX-listed shares of Mesoblast MSB.AX jump as much as 8.8% to A$1.800; marks biggest intraday pct gain since June 4

MSB hits highest since June 19

Stock biggest gainer on S&P/ASX 200 index .AXJO; set for sixth straight session of gains

Cell-therapy tech firm and U.S. FDA align on key items for Biologics License Application for its therapy product, Revascor

Revascor is being developed to treat advanced, end-stage chronic heart failure

Co intends to apply for accelerated FDA approval by 2025-end

MSB last up 7.3%, trimming YTD losses to 45%